A metabolic enzyme drives lymphoma and is a potential drug target

June 24, 2020

Because of how aggressively they divide, cancer cells have an increased demand for building materials and energy. They meet these added demands by altering their metabolism -- taking in larger amounts of fuel, for example.

Historically, these metabolic changes have been considered a consequence rather than a cause of cancer, and therefore not good drug targets. However, a new study from the Sloan Kettering Institute laboratory of Hans-Guido Wendel challenges that assumption.

"We find that increased activity of a normal metabolic enzyme, called SHMT2, is sufficient to transform normal B cells into B cell lymphomas," says Sara Parsa, a postdoctoral fellow in the Wendel lab and the first author of a paper describing these results. The paper was published June 22 in the journal Nature Cancer.

Enzymes are proteins that speed up chemical reactions. SHMT2's main role is to speed the conversion of the amino acid serine into glycine, simultaneously generating a small molecule called a methyl group. This methyl group, the researchers found, binds to the on/off switch (called a promoter) of genes that encode previously unrecognized tumor suppressor proteins. This binding turns off these tumor suppressors, resulting in B cell lymphoma. (Because this change does not involve a change in the DNA sequence of genes, it is an example of epigenetics.)

SHMT2 sits on a region of chromosome 12 that is often amplified (present in multiple copies) in B cell lymphoma. The increased number of gene copies leads to more of the enzyme being made. In animals, this is enough to cause lymphomas.

Other cancer cells, the researchers note, also carry the same gene amplification and contain abundant SHMT2, revealing this to be a common theme that could be exploited therapeutically.

While scientists have documented previous links between metabolism and cancer, most of these involve metabolic proteins that are mutated (genetically altered). "This may be the first time that anyone has shown that too much of a normal metabolic enzyme can drive cancer," Dr. Wendel says. "It reinforces the idea that metabolic changes can be a cause rather than simply an effect of cancer."

He notes that the research reveals that SHMT2 could be a potential drug target for cancer therapies, provided there is a way to target it specifically in cancer cells.
-end-
The study received financial support from the NCI Cancer Center Support Grant (P30 CA08748), NIH SPORE grants in Lymphoma and Soft Tissue Sarcoma, the Starr Cancer Consortium, the Lymphoma Research Foundation, the National Institutes of Health (RO1CA183876-05, RO1CA207217-03), and the Leukemia and Lymphoma Society. The study authors declare no competing interests.

About Memorial Sloan Kettering (MSK)

We are the world's oldest and largest private cancer center, devoting more than 135 years to world-class patient care, innovative research, and distinguished educational programs. MSK is home to more than 20,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. Today, we are one of 51 National Cancer Institute (NCI) designated Comprehensive Cancer Centers, with state-of-the-art-science flourishing side by side with clinical studies, personalized treatment, and compassionate care. Year after year, we are among the top two cancer hospitals nationwide, and frequently recognized for our expertise in specific adult and pediatric specialties. And our always-evolving educational programs train new leaders in the field, here and around the world. http://www.mskcc.org.

Memorial Sloan Kettering Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.